Galectin Therapeutics Inc.
GALTHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. With a market capitalization of $321.7M, it sits in small-cap territory. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Market Cap
$321.7M
Beta
0.38
P/E (TTM)
—
P/E (Fwd)
-1.90
EPS (TTM)
$-0.43
EPS (Fwd)
$-1.68
ROE
—
ROA
-64.2%
Cash
$13.3M
Total Debt
$144.0M
Free CF
-$14.9M
52W Change
-37.5%
Annual Financials
Cash vs Debt
Where GALT stands vs its 150-day and 200-day moving averages
As of the September 28, 2026 close, GALT finished 22.64% above its 150-day moving average ($3.18) and 17.47% above its 200-day moving average ($3.32). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GALT overbought or oversold?
At the September 28, 2026 close, GALT's RSI(14) was 28.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $13.3M in cash, though total debt stands at $144.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$14.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
With a beta below 0.7, Galectin Therapeutics Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing GALT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.